Infliximab for the treatment of ulcerative colitis.
Infliximab (IFX), an anti-TNF biologic agent, has been demonstrated to offer benefits for the treatment of autoimmune disorders, such as rheumatoid arthritis and Crohn's disease. Several trials have also investigated the efficacy of IFX for the treatment of ulcerative colitis (UC). IFX was found to be well tolerated. In most trials, IFX treatment was more effective than placebo for patients with moderate, moderate-to-severe or severe UC. However, its place in the treatment algorithms for UC remains to be defined and, to this end, clinical trials comparing IFX treatment to conventional therapies are needed.
Eshuis
Emma J
EJ
Department of Surgery, Academic Medical Center, 1105 AZ, Amsterdam, The Netherlands. e.j.eshuis@amc.uva.nl
Bemelman
Willem A
WA
Stokkers
Pieter C F
PC
D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D000069285:Infliximab; D011788:Quality of Life / Q000523:psychology; D013256:Steroids / Q000627:therapeutic use; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D013256:Steroids; D000069285:Infliximab